Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Aggarwal

Showing results (241-250 of 262) with videos related to

Pageof 27
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|November 7, 2017
2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major SubgroupsIngrid E Lundberg, Anna Tjärnlund, Matteo Bottai, et al.
Annals of the Rheumatic Diseases|October 29, 2017
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroupsIngrid E Lundberg, Anna Tjärnlund, Matteo Bottai, et al.
RMD Open|November 28, 2017
EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology reportMatteo Bottai, Anna Tjärnlund, Giola Santoni, et al.
Rheumatology International|October 22, 2022
COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) surveyLeonardo Santos Hoff, Naveen Ravichandran, Samuel Katsuyuki Shinjo, et al.
Arthritis and Rheumatism|September 28, 2010
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological reportTuhina Neogi, Daniel Aletaha, Alan J Silman, et al.
The New England Journal of Medicine|March 30, 2026
A Phase 3 Trial of Brepocitinib in DermatomyositisRuth Ann Vleugels, Julie J Paik, Iazsmin Bauer Ventura, et al.
Rheumatology (Oxford, England)|March 24, 2023
Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period-a cross-sequential study based on COVAD surveysKshitij Jagtap, R Naveen, Jessica Day, et al.
Rheumatology (Oxford, England)|March 2, 2024
Characteristics of and risk factors for COVID-19 breakthrough infections in idiopathic inflammatory myopathies: results from the COVAD studyLeonardo Santos Hoff, Naveen Ravichandran, Parikshit Sen, et al.
Rheumatology (Oxford, England)|April 21, 2023
Flares in IIMs and the timeline following COVID-19 vaccination: a combined analysis of the COVAD-1 and -2 surveysNaveen R, Parikshit Sen, Zoltán Griger, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 28, 2024
Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome ProjectSara Faghihi-Kashani, Akira Yoshida, Francisca Bozan, et al.
Pageof 27

Showing results (241-250 of 262) with videos related to

Sort By:
Pageof 27
Arthritis & Rheumatology (Hoboken, N.J.)|November 7, 2017
2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major SubgroupsIngrid E Lundberg, Anna Tjärnlund, Matteo Bottai, et al.
Annals of the Rheumatic Diseases|October 29, 2017
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroupsIngrid E Lundberg, Anna Tjärnlund, Matteo Bottai, et al.
RMD Open|November 28, 2017
EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology reportMatteo Bottai, Anna Tjärnlund, Giola Santoni, et al.
Rheumatology International|October 22, 2022
COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) surveyLeonardo Santos Hoff, Naveen Ravichandran, Samuel Katsuyuki Shinjo, et al.
Arthritis and Rheumatism|September 28, 2010
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological reportTuhina Neogi, Daniel Aletaha, Alan J Silman, et al.
The New England Journal of Medicine|March 30, 2026
A Phase 3 Trial of Brepocitinib in DermatomyositisRuth Ann Vleugels, Julie J Paik, Iazsmin Bauer Ventura, et al.
Rheumatology (Oxford, England)|March 24, 2023
Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period-a cross-sequential study based on COVAD surveysKshitij Jagtap, R Naveen, Jessica Day, et al.
Rheumatology (Oxford, England)|March 2, 2024
Characteristics of and risk factors for COVID-19 breakthrough infections in idiopathic inflammatory myopathies: results from the COVAD studyLeonardo Santos Hoff, Naveen Ravichandran, Parikshit Sen, et al.
Rheumatology (Oxford, England)|April 21, 2023
Flares in IIMs and the timeline following COVID-19 vaccination: a combined analysis of the COVAD-1 and -2 surveysNaveen R, Parikshit Sen, Zoltán Griger, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 28, 2024
Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome ProjectSara Faghihi-Kashani, Akira Yoshida, Francisca Bozan, et al.
Pageof 27